PROCESS FOR THE PREPARATION OF A TETRAZOLE DERIVATIVE IN TWOCRYSTALLINE FORMS AND NOVEL CRYSTALLINE FORM OF SAID DERIVATIVE

摘要

The present invention relates to a process for the preparation of the 2-n.butyl-3-[[2'-(tetrazol-5-yl) biphenyl-4-yl] methyl]-1,3-diazaspiro[4.4]- non-1-en-4-one by reaction of the corresponding nitrile with an alkaline azide and triethylamine hydrochloride, recovering the 2-n.butyl-3-[[2'- (tetrazol-5-yl) biphenyl-4-yl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one in form of one of its alkaline salts in aqueous solution, by neutralization of said alkaline salt and crystallization of the 2-n.butyt-3-[[2'-(tetrazol-5-y l)- biphenyl-4-yl]methyl]-1,3-diazaspiro[4.4] non-1-en-4-one thus precipitated either in a solvent containing less than 10% of water or in a solvent containing more than 10% of water in order to obtain two different crystalline forms (Forms A and B). Furthermore a novel crystalline form (Form B) of 2-n.butyl-3-[[2'-(tetrazol-5-yl)biphenyl-4-yl] methyl]-1,3- diazaspiro[4.4] non-1-en-4-one and pharmaceutical compositions containing it are described. Form A has the X-ray powder diffraction pattern given in Table II: TABLE II d I/l o 18.98 100.00 10.89 5.81 9.49 7.43 8.48 6.60 7.13 46.23 6.68 11.25 6.30 7.45 5.45 8.85 5.22 16.82 5.03 11.81 4.71 15.91 4.58 45.40 4.44 26.12 4.32 25.44 4.22 25.86 4.11 21.72 3.93 25.46 3.85 33.89 32 3.77 27.76 3.38 9.09 3.33 11.75 3.23 13.68 3.14 11.99 2.80 8.97 2.71 9.50 Form B has the X-ray powder diffraction pattern given in Table I: TABLE I d I/l o 11.22 100.00 7.90 12.02 7.52 13.79 7.23 18.60 6.27 20.14 6.09 6.47 5.86 7.42 5.60 98.76 5.41 19.45 5.05 24.67 4.97 20.36 4.91 12.92 4.80 27.33 4.61 15.90 4.49 14.73 4.36 9.86 4.17 62.84 4.07 15.39 3.97 30.34 3.88 14.32 3.83 13.56 3.75 37.28 3.53 26.48 3.46 12.42 3.40 27.88 3.27 11.03 3.18 10.42 3.15 7.28 3.12 6.11 3.05 15.50 3.01 9.49 2.81 7.11 2.78 9.40